ka lapaʻau ʻana no ka maʻi maʻi maʻi renal cell carcinoma

Lapaʻau no ka maʻi maʻi maʻi renal cell carcinoma (RCC) pili i nā ʻano hana like ʻole, me ka ʻoki ʻana, ka lāʻau lapaʻau i manaʻo ʻia, immunotherapy, a me ka radiation therapy. ʻO ke koho o lapaʻau pili i nā mea e like me ka pae o ka maʻi kanesa, ke olakino holoʻokoʻa o ka mea maʻi, a me nā makemake o kēlā me kēia kanaka. He mea koʻikoʻi ka ʻike mua ʻana a me ka manawa kūpono no ka hoʻomaikaʻi ʻana i nā hopena.ʻO ka maʻi maʻi maʻi kino (RCC) ʻo ia ke ʻano maʻamau o ka maʻi maʻi ʻaʻai maʻamau i nā pākeke. Hoʻomaka ia ma ka uhi o ka tubule convoluted proximal, ka ʻāpana o ka puʻupaʻa e kānana i ke koko a hoʻoneʻe i nā mea ʻōpala. ʻOiai ʻaʻole maopopo mau ke kumu o ka RCC, pili kekahi mau mea pilikia i ka ulu ʻana o ka maʻi. ʻO kēia mau mea pilikia e pili ana i ka puhi paka, ka momona, ke koko kiʻekiʻe, a me nā kūlana genetic e like me ka maʻi von Hippel-Lindau (VHL). Ma ka Shandong Baofa Cancer Research Institute, ua kūpaʻa mākou i ka hāʻawi ʻana i ka ʻike piha a me ka holomua lapaʻau nā koho no ka poʻe maʻi RCC. Nā ʻano o ka maʻi maʻi maʻi maʻi Renal. lapaʻau. ʻO nā subtypes maʻamau ka: Holoi i ke kelepona RCC: ʻO kēia ka ʻano maʻamau loa, e helu ana ma kahi o 70-80% o nā hihia. Papillary RCC: ʻO ka lua o nā ʻano maʻamau, e hōʻike ana ma kahi o 10-15% o nā hihia. Chromophobe RCC: ʻO kahi ʻano liʻiliʻi maʻamau, e hana ana ma kahi o 5% o nā hihia. ʻOhi ʻana i ka duct RCC: ʻO kahi ʻano kakaʻikaʻi a me ka huhū o RCC. Nā Koho Lapaʻau no ka Renal Cell CarcinomaThe lapaʻau ʻO ka hoʻokokoke ʻana no RCC e pili ana i nā kumu he nui, me ka pae o ka maʻi kanesa, ke olakino holoʻokoʻa o ka mea maʻi, a me ke ʻano subtype o RCC. maʻamau lapaʻau ʻO ke kaʻina hana, ka lāʻau lapaʻau i hoʻopaʻa ʻia, ka immunotherapy, a me ka radiation therapy ka lapaʻau ʻana no ka maʻi maʻi maʻi renal cell carcinoma, ʻoi aku ka nui i ka wā e ʻike ʻia ai ka maʻi kanesa i ka puʻupaʻa. Loaʻa nā koho ʻokiʻoki: ʻO ka nephrectomy radical: Hoʻopili kēia i ka hoʻopau piha ʻana o ka puʻupaʻa i hoʻopilikia ʻia, me nā ʻiʻo a puni e like me ka adrenal gland a me nā lymph nodes. ʻO ka nephrectomy hapa: Hoʻopili kēia i ka wehe ʻana i ke koko a me kahi ʻāpana liʻiliʻi o ka ʻiʻo olakino, e mālama i ka nui o ka puʻupaʻa e like me ka hiki. ʻOi aku ka makemake o kēia ʻano no nā maʻi koko liʻiliʻi a i ʻole he hoʻokahi puʻupaʻa ka mea maʻi. Hiki i kēia mau lāʻau lapaʻau ke hana maikaʻi loa i ka RCC kiʻekiʻe. ʻO nā lāʻau lapaʻau maʻamau i manaʻo ʻia he: ʻO nā mea pale VEGF: Hoʻopaʻa kēia mau lāʻau lapaʻau i ke ala o ka vascular endothelial growth factor (VEGF), he mea nui ia no ke kūkulu ʻana i nā kīʻaha koko hou e hāʻawi ana i nā maʻi maʻi. ʻO nā laʻana he sunitinib (Sutent), sorafenib (Nexavar), pazopanib (Votrient), axitinib (Inlyta), a me cabozantinib (Cabometyx). nā mea hoʻopaneʻe mTOR: Hoʻopaʻa kēia mau lāʻau lapaʻau i ke ala mammalian o ka rapamycin (mTOR), kahi e hoʻoponopono ai i ka ulu ʻana o nā cell a me ka metabolism. ʻO nā laʻana he temsirolimus (Torisel) a me everolimus (Afinitor). ʻO nā lāʻau lapaʻau immunotherapy no RCC penei: ʻO nā mea hoʻopaʻa hoʻopaʻa kino: Hoʻopaʻa kēia mau lāʻau i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā maʻi maʻi maʻi. ʻO nā laʻana he nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), a me atezolizumab (Tecentriq). Hoʻohui pinepine ʻia ʻo Nivolumab me ka ipilimumab no ka maʻi maʻi. Cytokines: ʻO ka interleukin-2 (IL-2) kiʻekiʻe a me ka interferon-alpha (IFN-α) nā cytokines e hiki ke hoʻoulu i ka ʻōnaehana pale. Eia nō naʻe, hiki i kēia mau lāʻau lapaʻau ke loaʻa nā hopena koʻikoʻi a ʻaʻole i hoʻohana pinepine ʻia i kēia manawa ma muli o ka loaʻa ʻana o nā immunotherapies hou. ʻAʻole ia ka mea mua ka lapaʻau ʻana no ka maʻi maʻi maʻi renal cell carcinoma, akā hiki ke hoʻohana ʻia no ka mālama ʻana i ka ʻeha a i ʻole nā hōʻailona ʻē aʻe i hoʻokumu ʻia e ka maʻi maʻi maʻi nui i laha i nā wahi ʻē aʻe o ke kino. Hoʻohana ʻia ia i kekahi manawa ma hope o ka ʻoki ʻana inā loaʻa ka pilikia e hoʻi hou mai ke kanesa a inā ʻaʻole hiki ke wehe ʻia kekahi o ke koko. Hāʻawi ka Stereotactic body radiation therapy (SBRT) i nā haʻahaʻa kiʻekiʻe o ka radiation i kahi i kuhikuhi pono ʻia a hoʻohana ʻia i kekahi manawa no nā maʻi maʻi ʻaʻai. lapaʻau hoʻokokoke. Hoʻokumu ʻia ke kahua ma ka nui a me ka wahi o ka ʻōpū, inā paha ua laha ʻia i nā puʻupuʻu lymph kokoke, a inā paha ua metastasized i nā kino mamao. ʻO ka Stage I Renal Cell Carcinoma ʻO ka maʻi maʻi i hoʻopaʻa ʻia i ka puʻupaʻa a he 7 knm a emi mai paha ke anawaena. Lapaʻau 'O ka mea ma'amau e pili ana i ka wehe 'ana i ka ma'i koko, ma o ka nephrectomy hapa a i 'ole radical. Stage II Renal Cell Carcinoma 'Oi aku ka nui o ka ma'i ma'i ma mua o 7 knm akā pa'a na'e i ka puki. Lapaʻau 'O ka mea ma'amau ka nephrectomy radical. Stage III Renal Cell Carcinoma Ua laha ka ma'i ma'i i nā puna lymph kokoke a i 'ole ua ulu a lilo i mau a'a nui a i'ole nā'i'o puni. Lapaʻau hiki ke komo i ka radical nephrectomy, lymph node dissection, a me ka adjuvant therapy (e laʻa. Lapaʻau Hiki i nā koho ke komo i ka ʻoki ʻana no ka wehe ʻana i ka maʻi maʻi mua (cytoreductive nephrectomy), ka lapaʻau i hoʻopaʻa ʻia, immunotherapy, radiation therapy, a i ʻole ka hui pū ʻana o kēia mau ala. He koho paha nā hoʻokolohua lapaʻau. ʻO ka noho ʻana me Renal Cell Carcinoma ʻO ka noho ʻana me RCC hiki ke hōʻike i nā pilikia like ʻole, ma ke kino a me ka naʻau. Pono ka loaʻa ʻana o kahi ʻōnaehana kākoʻo ikaika a loaʻa i ka mālama olakino holoʻokoʻa. Hiki i nā maʻi ke loaʻa nā hopena ʻaoʻao mai lapaʻau, e like me ka luhi, nausea, ka ma'i pa'i, a me ka ma'i 'ili. ʻO ka mālama ʻana i kēia mau hopena ʻaoʻao he ʻāpana koʻikoʻi o ka mālama maʻi kanesa. Eia kekahi, ʻo ka mālama ʻana i kahi nohona olakino, me ka ʻai kaulike a me ka hoʻomaʻamaʻa maʻamau, hiki ke kōkua i ka hoʻomaikaʻi ʻana i ka maikaʻi holoʻokoʻa. Ma Shandong Baofa Cancer Research Institute, hāʻawi kā mākou hui hoʻolaʻa i ka mālama aloha a pilikino lapaʻau hoʻolālā e kōkua i nā maʻi e hoʻokele i kā lākou RCC a hoʻomaikaʻi i ko lākou ola. Aia mākou ma Jinan Innovation Zone, a ua kūlike kā mākou misionari me ka hoʻolālā 'Made in China 2025'. ʻO nā holomua hou ma Renal Cell Carcinoma TreatmentThe field of RCC lapaʻau ke ulu mau nei, me nā lāʻau lapaʻau hou a me nā ala e hoʻomohala ʻia. Loaʻa nā holomua hou: Hoʻohui Immunotherapy: ʻO ka hui pū ʻana i nā lāʻau lapaʻau immunotherapy like ʻole, e like me nivolumab a me ipilimumab, ua hōʻike i nā hopena maikaʻi aʻe i kekahi mau maʻi me ka RCC kiʻekiʻe. Nā lāʻau lapaʻau i hoʻomaikaʻi ʻia: Ke kūkulu ʻia nei nā hanauna hou o nā lāʻau lapaʻau i hoʻopaʻa ʻia me ka maikaʻi o ka maikaʻi a me ka liʻiliʻi o nā hopena ʻaoʻao. Lapaau pilikino: Ke hana nei nā mea noiʻi e ʻike i nā biomarkers hiki ke kōkua i ka wānana i nā mea maʻi e pane aku i kahi kikoʻī lapaʻaus.Prognosis for Renal Cell CarcinomaHe ʻokoʻa ka wānana no RCC ma muli o ka pae o ka maʻi kanesa, ke olakino holoʻokoʻa o ka mea maʻi, a me ka pane ʻana i lapaʻau. He mea koʻikoʻi ka ʻike mua ʻana a me ka manawa kūpono no ka hoʻomaikaʻi ʻana i nā hopena. ʻO ka poʻe maʻi me ka RCC kūloko i hana ʻia i ke kaʻina he nui ka manawa e ola ai. Eia naʻe, ʻaʻole maikaʻi ka prognosis no nā poʻe maʻi me ka RCC kiʻekiʻe. Hoʻomau ka noiʻi ʻana i ka hoʻomohala ʻana i nā mea hou a ʻoi aku ka maikaʻi lapaʻaus e hoʻomaikaʻi i ka wānana no nā mea maʻi āpau me RCC. lapaʻaus a i ʻole nā ala no RCC. ʻO ka komo ʻana i kahi hoʻokolohua lapaʻau hiki ke hāʻawi i ke komo ʻana i nā lāʻau lapaʻau ʻokiʻoki ʻaʻole i loaʻa ākea. Pono nā poʻe maʻi e makemake e aʻo hou e pili ana i nā hoʻokolohua lapaʻau e kamaʻilio me kā lākou kauka. Laʻana Ikepili: Ka helu o ke ola ma ka pae o ka pae 5-makahiki ola ola ʻo Stage I 81-93% Stage II 74-91% Stage III 53-83% Stage IV 8-20% Puna: American Cancer Society (www.cancer.org)